Protein kinases and Parkinson’s disease

Syed Jafar Mehdi, Hector Rosas-Hernandez, Elvis Cuevas, Susan M. Lantz, Steven W. Barger, Sumit Sarkar, Merle G. Paule, Syed F. Ali, Syed Z. Imam

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Currently, the lack of new drug candidates for the treatment of major neurological disorders such as Parkinson’s disease has intensified the search for drugs that can be repurposed or repositioned for such treatment. Typically, the search focuses on drugs that have been approved and are used clinically for other indications. Kinase inhibitors represent a family of popular molecules for the treatment and prevention of various cancers, and have emerged as strong candidates for such repurposing because numerous serine/threonine and tyrosine kinases have been implicated in the pathobiology of Parkinson’s disease. This review focuses on various kinase-dependent pathways associated with the expression of Parkinson’s disease pathology, and evaluates how inhibitors of these pathways might play a major role as effective therapeutic molecules.

Original languageEnglish (US)
Article number1585
JournalInternational journal of molecular sciences
Issue number9
StatePublished - Sep 20 2016
Externally publishedYes


  • Dopamine
  • Kinase inhibitors
  • Parkinson’s disease
  • Serine/threonine kinase
  • Tyrosine kinase

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Protein kinases and Parkinson’s disease'. Together they form a unique fingerprint.

Cite this